advertisement
Abstract #65903 Published in IGR 17-3
Imaging mass spectrometry of the visual system: Advancing the molecular understanding of retina degenerations
Bowrey HE; Anderson DM; Pallitto P; Gutierrez DB; Fan J; Crouch RK; Schey KL; Ablonczy ZProteomics - Clinical Applications 2016; 10: 391-402
Visual sensation is fundamental for quality of life, and loss of vision to retinal degeneration is a debilitating condition. The eye is the only part of the central nervous system that can be non-invasively observed with optical imaging. In the clinics, various spectroscopic methods provide high spatial resolution images of the fundus and the developing degenerative lesions. However, the currently utilized tools are not specific enough to establish the molecular underpinnings of retinal diseases. In contrast, imaging mass spectrometry (IMS) is a powerful tool to identify molecularly specific disease indicators and classification markers. This technique is particularly well suited to the eye, where molecular information can be correlated with clinical data collected via non-invasive diagnostic imaging modalities. Recent studies during the last few recent years have uncovered a plethora of new spatially-defined molecular information on several vision-threatening diseases, including age-related macular degeneration (AMD), Stargardt disease, glaucoma, cataract, as well as lipid disorders. Even though mass spectrometry inside the eye cannot be performed non-invasively, by linking diagnostic and molecular information, these studies are the first step toward the development of smart ophthalmic diagnostic and surgical tools. Here we provide an overview of current approaches applying IMS technology to ocular pathology. This article is protected by copyright. All rights reserved.
Brain Health Institute, Rutgers University.
Full articleClassification:
6.30 Other (Part of: 6 Clinical examination methods)
2.13 Retina and retinal nerve fibre layer (Part of: 2 Anatomical structures in glaucoma)
